Skip to content
Trial Eligibility
Menu

Clinical Trials Recruiting near Salt Lake City, UT

984 clinical trials have a recruiting site within 25 miles of Salt Lake City, Utah, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Studies enrolling near Salt Lake City

Showing 30 studies, nearest first.
  1. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    NCT05174169

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  2. MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

    NCT03072927

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  3. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    NCT05946213

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  4. Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)

    NCT05141396

    • Interventional
    • Ages 16 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 25 mi
  5. A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

    NCT06866405

    • Phase 3
    • Ages 0 years and older
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 25 mi
  6. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    NCT07645924

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 25 mi
  7. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    NCT07674654

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 25 mi
  8. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  9. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  10. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  11. Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

    NCT06218875

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  12. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  13. High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

    NCT06992427

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  14. BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

    NCT07160244

    • Phase 3
    • Ages 1 day to 49 years
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  15. Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

    NCT07181109

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 25 mi
  16. Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease

    NCT01099982

    • Observational
    • Ages 13 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  17. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  18. Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

    NCT04510597

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  19. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    NCT04858334

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  20. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    NCT05040360

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  21. Trident Multi-tined Cannula for Cervical MBRFA Compared to the Conventional Cannula

    NCT05424198

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  22. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

    NCT05640999

    • Phase 2
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  23. mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

    NCT05677490

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  24. Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

    NCT06203600

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  25. Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

    NCT06316297

    • Phase 1/2
    • Ages 18 to 45 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  26. A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

    NCT06541704

    • Phase 3
    • Ages 50 to 85 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  27. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

    NCT06580314

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  28. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    NCT06931340

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  29. Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

    NCT07061977

    • Phase 3
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi
  30. Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

    NCT07198074

    • Phase 3
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 25 mi

By condition

Clinical trials in Salt Lake City by condition

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.